Invitro activity of tigecycline against Gram positive and Gram negative isolates in a tertiary care hospital

Journal of Clinical and Diagnostic Research

Volumn 5, Issue 8, 2011, Pages 1559-1563

  Shanthi, M ^a   Sekar, Uma ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Anti microbial resistance; In vitro susceptibility; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CRITERION VARIABLE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; TERTIARY HEALTH CARE;

ACINETOBACTER BAUMANNII; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; SERRATIA; STREPTOCOCCUS PNEUMONIAE;

EID: 84856145675     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rossi F, Garcia P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobialresistance in Latin America (2004-2007) and in vitro activityof the glycylcycline tigecycline and of other antibiotics. Braz J InfectDis 2008;12 (5):405-15.
2. Behera B, Das A, Mathur P, Kapil A, Gadepalli R, Dhawan B. Tigecyclinesusceptibility report from an Indian tertiary care hospital. Indian J MedRes 2009;129:446-50.
3. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobialsusceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST andthe invitro activity of tigecycline. J Antimicrob Chemother 2007;60:1018-29.
4. Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M, Kiem S, KimYS, et al. Lee NY and the Asian network for surveillance of resistantpathogens (ANSORP) study group. Emergence in Asian countries ofStaphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob agents Chemother 2004; 48 (12): 4926-28.
5. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80
6. Livermore DM. Tigecycline: what is it and where should it be used? JAntimicrob Chemother 2005;56:611-14.
7. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. In vitro activitiesof tigecycline combined with other anti-microbials against multiresistantGram-positive and Gram-negative pathogens. J AntimicrobChemother 2008;61:371-74.
8. Morosini MI, Castillo MG, Coque TM, Valverde A, Novais A, Loza E, Baquero F, et al. Antibiotic coresistance in extended-spectrum lactamase-producing Enterobacteriaceae and in vitro activity oftigecycline. Antimicrob agents Chemother 2006; 50(8):2695-2699.
9. CLSI. Performance standards for Antimicrobial Susceptibility Testing:seventeenth Informational Supplement. CLSI document M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
10. Brown SD, Traczewski MM. Comparative in vitro anti-microbial activityof tigecycline, a new glycylcycline compound in freshly preparedmedium and quality control. J Clin Microbiol 2007;45 (7): 2173-79.
11. Manoharan A, Chatterjee S, Madhan S, Mathai D. Evaluation oftigecycline activity in clinical isolates among Indian medical centers. Indian J Pathol Microbiol 2010;53 (4):734-37.
12. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecyclinefor the treatment of multidrug-resistant (including carbapenemresistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62:45-55.
13. Sorlozano A, Gutierrez J, Roman E, Luna JD, Roman J, Liebana J, et al. A comparison of the activity of tigecycline against multiresistantclinical isolates of Staphylococcus aureus and Streptococcusagalactiae. Diagn Microbial Infect Dis 2007;58 (4): 487-89.
14. Giamarellou H, Poulakou G. Multi-drug resistant Gram negativeinfections: what are the treatment options? Drugs 2009;69 (14):1879-901.
15. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterisationof a vancomycin resistant Staphylococcus aureus isolated fromKolkata (South Asia). J Med Microbiol 2008;57:72-79.
16. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcusaureus (VRSA) from a tertiary care hospital from northern part of India. Infect Dis 2006; 6: 156.
17. Thati V, Channappa T, Shivannar T, Gaddad SM. Vancomycin resistanceamong methicillin resistant Staphylococcus aureus isoaltes fromintensive care units of tertiary care hospitals on Hyderabad. Indian JMed Res 2011;134:704-08.
18. Sorlozano A, Gutierrez J, Salmeron A, Luna JD, Checa FM, Roman J, et al. Activity of tigecycline against clinical isolates of Staphylococcusaureus and extended spectrum β-lactamase-producing Escherichiacoli in Granada, Spain. Int J Antimicrob agents 2006;28:532-36.
19. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hseuh PR, andPaterson DL. Emergence of high levels of extended-spectrum
20. Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecyclineand colistin resistant Acinetobacter baumannii in patients with complicatedurinary tract infections in north India. Indian J Med Res2011;133:681-84.